Drug Profile
Research programme: growth factor receptor antagonists - Kyowa Hakko/Millennium
Latest Information Update: 19 Dec 2006
Price :
$50
*
At a glance
- Originator Kyowa Hakko; Millennium Pharmaceuticals
- Developer Millennium Pharmaceuticals
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 16 Dec 2003 No development reported - Preclinical for Reperfusion injury in USA (unspecified route)
- 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
- 17 Apr 1998 Preclinical development for Reperfusion injury in USA (Unknown route)